Incorporation of two doctors to the R&D&i within the "Torres Quevedo" program 2020 call


No votes yet
 
Related
Operating revenue in the first nine months of 2024 was 564.6 million euros, a 5% decrease on the first nine months of 2023, mainly due...
4 min
07/11/2024
Madrid, Spain - 24 October 2024 – Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, “ROVI”), a pan-European pharmaceutical company that...
2 min
24/10/2024
ROVI ACHIEVED OPERATING REVENUE OF 329.3 MILLION EUROS AND INCREASED ITS GROSS MARGIN BY 2.8 PERCENTAGE POINTS Operating revenue in...
7 min
31/07/2024